NEW YORK (GenomeWeb News) – Sequenom disclosed in a filing with the US Securities and Exchange Commission on Tuesday that it has reached a settlement with Ibis Biosciences in a patent infringement suit filed by Sequenom a year ago.

Under the agreement, Ibis will pay Sequenom $1 million within 30 days and the litigation will be dismissed. Under terms of the settlement agreement, Ibis and its parent company Abbott Laboratories will receive a non-exclusive license under three mass-spectrometry-based applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.